Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2019

01-04-2019 | Esophagus Resection | Thoracic Oncology

Lymph Node Progression and Optimized Node Dissection of Middle Thoracic Esophageal Squamous Cell Carcinoma in the Latest Therapeutic Surgical Strategy

Authors: Takafumi Soeno, MD, Hiroki Harada, MD, Kei Hosoda, MD, PhD, FACS, Hiroaki Mieno, MD, PhD, Akira Ema, MD, PhD, Hideki Ushiku, MD, PhD, Marie Washio, MD, Yoshimasa Kosaka, MD, PhD, Masahiko Watanabe, MD, PhD, FACS, Keishi Yamashita, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 4/2019

Login to get access

Abstract

Purpose

The aim of this study is to elucidate the optimized lymph node dissection range in middle thoracic (Mt) esophageal squamous cell carcinoma (ESCC) requiring surgery.

Patients and Methods

We retrospectively analyzed 165 ESCC patients who underwent surgery with curative intent between 2009 and 2016, including 99 (60%) with MtESCC. Preoperative chemotherapy was administered in more than 80% of cStage II/III MtESCC patients. The rates of pathological and potential metastasis (representing recurrences) to lymph nodes and prognosis (median follow-up 52 months) were clarified. Lymph node dissection efficacy was assessed by calculating the efficacy index (EI) for each lymph node.

Results

No. 2R had the highest rate of metastasis, with frequencies of 13/38/46% in cStage I/II/III, respectively, with the highest EI in MtESCC. Recurrences were seen in about 2–10% in the regional (nos. 1, 2L, 4R, and 10) and extraregional lymph nodes (paraaortic lymph node). The EI of lymph nodes was found to exhibit the highest score of 15 for no. 2R, followed by 11.5 for no. 17. The 5-year overall survival (OS) in MtESCC patients who underwent no. 2R lymph node dissection was 73.8%, while those who did not undergo no. 2R dissection did never reach 5-year OS (P = 0.002).

Conclusions

Meticulous lymph node dissection of no. 2R is the most important for long-term survival, and mandatory with the highest priority in MtESCC.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–86, 2015CrossRefPubMed
2.
Wu SG, Dai MM, He ZY, et al. Patterns of regional lymph node recurrence after radical surgery for thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 101:551–7, 2016CrossRefPubMed
3.
4.
Kumakura Y, Yokobori T, Yoshida T, et al. Elucidation of the anatomical mechanism of nodal skip metastasis in superficial thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 25:1221–1228, 2018CrossRefPubMedPubMedCentral
5.
Liu J, Liu Q, Wang Y, et al. Nodal skip metastasis is associated with a relatively poor prognosis in thoracic esophageal squamous cell carcinoma. Eur J Surg Oncol. 42:1202–5, 2016CrossRefPubMed
6.
Wang F, Zheng Y, Wang Z, et al. Nodal skip metastasis in esophageal squamous cell carcinoma patients undergoing three-field lymphadenectomy. Ann Thorac Surg. 104:1187–1193, 2017CrossRefPubMed
7.
Feng JF, Zhao Q, Chen QX. Prognostic value of subcarinal lymph node metastasis in patients with esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 14:3183–6, 2013CrossRefPubMed
8.
Niwa Y, Koike M, Hattori M, et al. The prognostic relevance of subcarinal lymph node dissection in esophageal squamous cell carcinoma. Ann Surg Oncol. 23:611–8, 2016CrossRefPubMed
9.
Miyata H, Yamasaki M, Makino T, et al. Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy. J Surg Oncol. 112:60–5, 2015CrossRefPubMed
10.
Wang ZQ, Deng HY, Hu Y, et al. Prognostic value of right upper mediastinal lymphadenectomy in Sweet procedure for esophageal cancer. J Thorac Dis. 8:3625–3632, 2016CrossRefPubMedPubMedCentral
11.
Hsu PK, Huang CS, Hsieh CC, et al. Role of right upper mediastinal lymph node metastasis in patients with esophageal squamous cell carcinoma after tri-incisional esophagectomies. Surgery. 156:1269–77, 2014CrossRefPubMed
12.
Yamashita K, Makino T, Yamasaki M, et al. Comparison of short-term outcomes between 2- and 3-field lymph node dissection for esophageal cancer. Dis Esophagus. 30:1–8, 2017CrossRef
13.
Yamashita K, Katada N, Moriya H, et al. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. Gen Thorac Cardiovasc Surg. 64:209–15, 2016CrossRefPubMed
14.
Yamashita K, Hosoda K, Moriya H, et al. Prognostic advantage of docetaxel/cisplatin/5-fluorouracil neoadjuvant chemotherapy in clinical stage II/III esophageal squamous cell carcinoma due to excellent control of preoperative disease and postoperative lymph node recurrence. Oncology. 92:221–228, 2017CrossRefPubMed
15.
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74, 2012CrossRefPubMed
16.
Harada H, Hosoda K, Moriya H, et al. Optimized lymph node dissection range during progression of lower thoracic esophageal squamous cell carcinoma in the latest therapeutic surgical strategy: A retrospective analysis. Oncol Lett. 16:3281–89, 2018PubMedPubMedCentral
17.
Hosoda K, Yamashita K, Katada N, et al. Impact of lower mediastinal lymphadenectomy for the treatment of esophagogastric junction carcinoma. Anticancer Res. 35:445–56, 2015PubMed
18.
Park SY, Kim DJ, Jung HS, et al. Relationship between the size of metastatic lymph nodes and positron emission tomographic/computer tomographic findings in patients with esophageal squamous cell carcinoma. World J Surg. 39:2948–54, 2015CrossRefPubMed
19.
Yu S, Lin J, Chen C, et al. Recurrent laryngeal nerve lymph node dissection may not be suitable for all early stage esophageal squamous cell carcinoma patients: an 8-year experience. J Thorac Dis. 8:2803–12, 2016CrossRefPubMedPubMedCentral
20.
Mine S, Watanabe M, Imamura Y, et al. Clinical significance of the pre-therapeutic nodal size in patients undergoing neo-adjuvant treatment followed by esophagectomy for esophageal squamous cell carcinoma. World J Surg. 41:184–90, 2017CrossRefPubMed
21.
Makino T, Yamasaki M, Miyata H, et al. Solitary lymph node recurrence of esophageal squamous cell carcinoma: surgical failure or systemic disease? Ann Surg Oncol. 23:2087–93, 2016CrossRefPubMed
Metadata
Title
Lymph Node Progression and Optimized Node Dissection of Middle Thoracic Esophageal Squamous Cell Carcinoma in the Latest Therapeutic Surgical Strategy
Authors
Takafumi Soeno, MD
Hiroki Harada, MD
Kei Hosoda, MD, PhD, FACS
Hiroaki Mieno, MD, PhD
Akira Ema, MD, PhD
Hideki Ushiku, MD, PhD
Marie Washio, MD
Yoshimasa Kosaka, MD, PhD
Masahiko Watanabe, MD, PhD, FACS
Keishi Yamashita, MD, PhD, FACS
Publication date
01-04-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07190-5

Other articles of this Issue 4/2019

Annals of Surgical Oncology 4/2019 Go to the issue

Gastrointestinal Oncology

Correlation Between Intraoperative and Pathological Findings for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Translational Research and Biomarkers

Is FGFR2 a Suitable Target to Treat Scirrhous-Type Gastric Cancer?

Melanoma

Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma

Melanoma

Postbiopsy Pigmentation is Prognostic in Head and Neck Melanoma

Urologic Oncology

Penile Cancer Management in the United States: Regional Centers of Expertise are Needed!

Colorectal Cancer

Treatment of Inguinal Lymph Node Metastases in Patients with Rectal Adenocarcinoma